Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
NCT01731990 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2025-04-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study got terminated based on result from primary endpoint analysis” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-23Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT04717635)
- 2025-10-24Also stopped (terminated): Novartis Pharmaceuticals, canakinumab + LNA043 (NCT04814368)
- 2025-10-16Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab (NCT04795466)
- 2025-10-10Also stopped (terminated): Novartis Pharmaceuticals, MBG453 + NIS793 (NCT04810611)
- 2025-07-30Results posted on the registry: Novartis Pharmaceuticals, canakinumab + LNA043 (NCT04814368)
- 2025-05-18Also stopped (terminated): Novartis Pharmaceuticals, spartalizumab + LAG525 (NCT03742349)
- 2025-05-06Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT04795466)
- 2025-04-08Results posted on the registry: Pancreatic Cancer Action Network, Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine (NCT04581343)
- 2025-03-11Results posted on the registry: Imperial College London, Canakinumab 150mg/ml solution for injection + Placebo (NCT03775109)
- 2024-10-09Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab + Placebo (NCT03447769)
- 2024-10-08Results posted on the registry: Novartis Pharmaceuticals, canakinumab + canakinumab-matching placebo (NCT03631199)
- 2024-07-11Phase 3 first posted: AO GENERIUM, GNR-086 + Ilaris® (NCT06497491)
- 2024-06-21Phase 3 first posted: AbbVie, Lutikizumab + Placebo (NCT06468228)
- 2024-06-20Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab + Pembrolizumab (NCT03968419)
- 2024-05-06Also stopped (terminated): University of Leipzig, Canakinumab Injection (NCT05237713)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision